TITLE

Ask the Experts

AUTHOR(S)
Galli, Annmarie; Palatnik, AnneMarie
PUB. DATE
April 2005
SOURCE
Critical Care Nurse;Apr2005, Vol. 25 Issue 2, p88
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides information on arterial and venous sheath removal after percutaneous coronary intervention (PCI). Background on bleeding complications after PCI; Anticoagulation therapies used for bleeding complications; Activated clotting time for removing a femoral sheath; Variation of protocols for sheath removal.
ACCESSION #
16582522

 

Related Articles

  • Sirolimus.  // Reactions Weekly;1/26/2008, Issue 1186, p34 

    The article describes the case of a 51-year-old man who developed total stent occlusion with thrombosis after undergoing implantation of a sirolimus-eluting stent. The patient received 300mg of antiplatelet drug clopidogrel before undergoing primary stenting of his left anterior descending...

  • Industry is pooling $100M for massive DAPT trial. McCarty, Mark // Medical Device Daily;10/17/2008, Vol. 12 Issue 221, p6 

    The article reports on the launch of a study on the effect of dual antiplatelet therapy (DAPT) on patients getting coronary artery stents in 2008. The study, which is slated to be completed in 2012, will evaluate stent thrombosis and major adverse cardiac and cerebrovascular events. Physician...

  • Non-cardiac surgery and antiplatelet therapy following coronary artery stenting. Luckie, M.; Khattar, R. S.; Fraser, D. // Heart;Aug2009, Vol. 95 Issue 16, p10 

    Coronary artery stenting is increasingly used as a treatment for coronary artery disease. A period of antiplatelet therapy is mandatory following coronary stenting, in order to minimise the risk of stent thrombosis. About 5% of patients who undergo coronary stenting will require non-cardiac...

  • Elective placement of covered stents in native coronary arteries. SØvik, E.; KlØw, N-E.; Brekke, M.; Stavnes, S.; Søvik, E; Kløw, N-E // Acta Radiologica;May2003, Vol. 44 Issue 3, p294 

    Purpose: To study the feasibility of placing a polytetrafluoroethylene (PTFE)-covered stent graft into native coronary arteries and assess the complications and the restenosis rate. Material and Methods: Fifty consecutive patients with stable angina pectoris were...

  • A bridge too far. Gunn, Julian // Heart;Feb2012, Vol. 98 Issue 4, p329 

    Images of left coronary angiogram showing anterior descending artery and myocardial fractional flow reserve (FFR) of patients before during and after stenting of the mid vessel fixed lesion and proximal muscular bridge.

  • ...and so does a similar study from Italy.  // Modern Medicine;Mar97, Vol. 65 Issue 3, p58 

    Presents an abstract of the study titled `Results of a coronary stenting for restenosis,' by A. Colombo, M. Ferraro et al, published in the October 1996 issue of `Journal of the American College of Cardiology.'

  • Multivessel coronary stenting has many advantages over angioplasty.  // Modern Medicine;Mar98, Vol. 66 Issue 3, p37 

    Discusses the abstract of the article `Long-Term Angiographic and Clinical Outcome of Patients Undergoing Multivessel Coronary Stenting,' by I. Moussa, B. Reimers et al, which appeared in the December 2, 1997 issue of `Circulation.'

  • Spontaneous Spinal Epidural Hematoma After Combined Urokinase and Heparin Thrombolytic Therapy for Deep Venous Thrombosis. Krieger, Nancy R.; Mehigan, John Thomas // Vascular Surgery;Jan/Feb1996, Vol. 30 Issue 1, p67 

    The literature clearly supports the view that all anticoagulation therapy is associated with a significant risk of hemorrhagic complications. Combining anticoagulation and fibrinolytic therapy further adds to this risk. Moreover, in the treatment of deep venous thrombosis the combined use of...

  • Antithrombotic efficacy and excess bleeding: a fine balance. Rao, A. Koneti // Hem/Onc Today;5/25/2008, Vol. 9 Issue 9, p2 

    The author reflects on the therapeutic efficacy and excessive bleeding linked with antithrombotic agents. It says that more potent antithrombotic agents come with efficacy but enhanced bleeding risk. Pharmacologic treatments come with the premise that they interrupt a mechanism involved in clot...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics